| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(73)92196-X |
| P698 | PubMed publication ID | 4121842 |
| P2093 | author name string | A P Kendal | |
| A S Monto | |||
| P2860 | cites work | Antibody against influenza A2 virus neuraminidase in human sera | Q36252420 |
| Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines | Q36252894 | ||
| Antibody response in man to influenza virus neuraminidase following influenza | Q37131288 | ||
| The Tecumseh study of respiratory illness. I. Plan of study and observations on syndromes of acute respiratory disease | Q40923779 | ||
| The Hong Kong-68 influenza A2 variant | Q43207962 | ||
| Haemagglutinin Relationships of Hong Kong(H3) and Asian(H2) Influenza Strains Delineated by Antigen-Specific Recombinants | Q43208289 | ||
| Association of serum anti-neuraminidase antibody with resistance to influenza in man. | Q44693807 | ||
| The structural relationship of sialidase to the influenza virus surface | Q45711418 | ||
| Functional significance of sialidose during influenza virus multiplication | Q45808892 | ||
| Influenza virus neuraminidase and the viral surface | Q45810320 | ||
| Reactions of antibodies with surface antigens of influenza virus | Q45810478 | ||
| Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren | Q57116598 | ||
| The polypeptide composition of influenza A viruses | Q64383482 | ||
| The in vivo production of "new" influenza A viruses. II. In vivo isolation of "new" viruses | Q93721792 | ||
| P433 | issue | 7804 | |
| P304 | page(s) | 623-625 | |
| P577 | publication date | 1973-03-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Effect of neuraminidase antibody on Hong Kong influenza | |
| P478 | volume | 1 |
| Q90566983 | A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoie |
| Q28830491 | A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens |
| Q50686159 | A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. |
| Q37626927 | A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses |
| Q30379967 | A review of the changes to the licensing of influenza vaccines in Europe. |
| Q42133050 | A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins |
| Q33474344 | A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets |
| Q30571702 | An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo |
| Q54217203 | Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals. |
| Q41922130 | Antibody responses after repeated influenza A virus immunizations among schoolchildren in Japan |
| Q64064390 | Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies |
| Q92461239 | Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus |
| Q37625970 | Characteristics of vaccine failures in a randomized placebo-controlled trial of inactivated influenza vaccine in children. |
| Q30380287 | Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase. |
| Q35408014 | Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel |
| Q45324380 | Comparison of the Efficacy of N9 Neuraminidase-specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection |
| Q36075789 | Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. |
| Q57116276 | Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain |
| Q57158300 | Correlates of Protection Against Influenza |
| Q30379517 | Cross-protection against European swine influenza viruses in the context of infection immunity against the 2009 pandemic H1N1 virus: studies in the pig model of influenza. |
| Q30359842 | Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. |
| Q45890584 | Description of a technique for the analysis of antineuraminidase antibodies oriented to H2N2 and H3N2 influenza virus strains |
| Q24615003 | Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses |
| Q52627557 | Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines. |
| Q37123064 | Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model |
| Q30429009 | Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial |
| Q42225065 | Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus |
| Q56880026 | Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine |
| Q34291098 | Fast vaccine design and development based on correlates of protection (COPs). |
| Q33907707 | Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations |
| Q90287155 | Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance |
| Q92668026 | Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection |
| Q33760887 | Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents |
| Q30398002 | Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015 |
| Q33820732 | In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen |
| Q52602393 | Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. |
| Q30386612 | Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response. |
| Q34121109 | Influenza hemagglutinin and neuraminidase membrane glycoproteins |
| Q30399269 | Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir |
| Q22305643 | Influenza pandemics of the 20th century |
| Q30322979 | Intranasal immunization with inactivated influenza vaccine. |
| Q41918783 | Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses |
| Q30409789 | Live Victoria/75- ts -1[E] Influenza A Virus Vaccines in Adult Volunteers: Role of Hemagglutinin Immunity in Protection Against Illness and Infection Caused by Influenza A Virus |
| Q52609074 | NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? |
| Q57094018 | Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness |
| Q39668475 | Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type |
| Q36408162 | Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets |
| Q39810755 | Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. |
| Q30472797 | New approaches to influenza chemotherapy. Neuraminidase inhibitors |
| Q89723360 | Next-generation influenza vaccines: opportunities and challenges |
| Q35826733 | Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future |
| Q30404256 | Pandemic influenza: certain uncertainties |
| Q36306922 | Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination |
| Q92125288 | Persistence of H7N9 virus antibody response 2 years after infection |
| Q38580454 | Prospects for broadly protective influenza vaccines |
| Q30418452 | Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice |
| Q92405122 | Protective Antibodies Against Influenza Proteins |
| Q40334782 | Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry |
| Q36462309 | Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines |
| Q33847234 | Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children |
| Q36257974 | Responses of volunteers to inactivated influenza virus vaccines |
| Q40492511 | Secretory anti-influenza immunity |
| Q64060443 | Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections |
| Q30373917 | Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers. |
| Q45888913 | Standardization of a rapid modified micro-neuraminidase-inhibition test (Essen-NIT) for influenza virus-neuraminidase antibody assay and comparison with the W.H.O. method |
| Q28297557 | Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans |
| Q27485986 | Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses |
| Q35540405 | Targeting B cell responses in universal influenza vaccine design |
| Q57094348 | The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine |
| Q42136996 | The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis |
| Q30403251 | The influenza pandemic of 2009: lessons and implications |
| Q92578680 | The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain |
| Q30387513 | The new influenza A H1N1 virus: balancing on the interface of humans and animals |
| Q96304264 | Universal coronavirus vaccines: the time to start is now |
Search more.